Participated · Series A · Jul 2026

Proxima Fusion is Europe’s leading stellarator company and the first spin-out from the Max Planck Institute for Plasma Physics, developing commercial fusion power plants using the QI-HTS stellarator concept. The company is building Alpha, a net-energy stellarator demonstrator targeted for the early 2030s, and plans a follow-on commercial plant called Stellaris later in the decade. Proxima leads the Alpha project in partnership with the state of Bavaria, the Max Planck Institute for Plasma Physics and industrial partners including RWE, supported by an Alpha Alliance of more than 50 companies. Headquartered in Munich with offices in Zurich and Oxford, Proxima employs around 200 people across engineering, science and operations. Financially, Proxima has secured more than €650 million in funding to date, including about €95 million in public grants, and plans to expand engineering, manufacturing and magnet production capabilities as it advances toward demonstrator completion.

Led · Seed · Jul 2026

Aylight develops chip-scale multiwavelength lasers that generate multiple precisely spaced wavelengths from a single chip using a frequency-modulated comb (FM comb) architecture. The design reduces the need for multiple discrete lasers in optical communication systems and is intended to be manufacturable in existing semiconductor photonics foundries. The company targets AI data-center optical interconnects and high-precision frequency-modulated continuous-wave (FMCW) sensing for applications such as semiconductor inspection, metrology, industrial automation, and precision robotics. Aylight was founded in 2025 by Bahareh Marzban and Dmitry Kazakov following research at ETH Zürich. The startup plans to use its recent pre-seed funding to build its first foundry prototypes and grow its R&D team as it moves from research toward initial products.

Participated · Equity · Feb 2026

Founded in 2020 by ENT physician Dr. Laurent Bonnardot and industrial entrepreneur Benjamin Crevant, France-based MyC offers a software platform that digitises occupational health and first-line medical care for complex worksites such as energy, maritime, defence and other high-risk sectors. The system centralises medical records, automates processes like pharmaceutical and specialist consultation management, and generates regulatory reporting, all while maintaining strong data security and international compliance standards. Designed to function even with limited connectivity, the SaaS solution enables rapid, large-scale deployment across geographically dispersed sites. By replacing fragmented, site-specific tools, MyC gives large enterprises a single, actionable view of workforce health data. The company aims to provide tangible operational value to essential industries through improved efficiency and compliance. With fresh capital, MyC intends to enhance its product roadmap and expand its sales and marketing teams to accelerate international enterprise adoption. No revenue or user figures were disclosed in the article.

Participated · Series A · Jan 2026

Aviwell develops microbiome-based animal nutrition products that use native bacterial ecologies to enhance health, performance, and robustness in livestock. Powered by its proprietary Aneto AI-driven discovery platform, the company designs targeted microbial communities with clearly defined modes of action. Its initial commercial focus is on poultry and aquaculture, two sectors facing mounting sustainability and antibiotic-resistance challenges. To date, Aviwell has secured €11 million in Series A funding to accelerate R&D, validate and scale its microbial ecologies, and broaden access to its Aneto platform as a service. The fresh capital will also support deeper commercial engagement with partners and customers. Aviwell operates from headquarters in Toulouse, France, and maintains an additional office in Lowell, Massachusetts.

Led · Seed · Jan 2026

Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.